å»è¬å
pharmaceuticalsæ¬æŠç¥ã¯ããã€ãªã¹ã¯ã»ãã€ãªã¿ãŒã³ã®ããŒããã©ãªãªã§ããç¹èš±åããå®å®ãããã£ãã·ã¥ãããŒã«äŸåããåŸæ¥ã®å€§æè£œè¬äŒæ¥ãåé¿ãã代ããã«èšåºè©Šé𿮵éã®å»è¬åãä¿æããç Žå£çãªæè¡ãæããæ°èã®ãã€ãªãã¯ãããžãŒäŒæ¥ã«éäžçã«æè³ããŸãããã®æŠç¥ã®ãªã¿ãŒã³ã¯ãå®å®ããå»è¬å販売ã«ãããã®ã§ã¯ãªããæåããèšåºããŒã¿ãèŠå¶åœå±ã®æ¿èªããŸãã¯ãããã¯ãã¹ã¿ãŒè¬ã®çºå£²ãšãã£ãã€ãã³ãã«ãã£ãŠçãã䟡å€ã®åè©äŸ¡ã«ãã£ãŠããããããŸãã
éå»ã®ãªã¿ãŒã³ãã£ãŒã
ããã¯ãã¹ãæéïŒ 2021-01-04â2026-11-19
ææ°ã®ã¢ããããŒã
--
æŠç¥ããŒããã©ãªãªã®è©³çް

é¢é£ãã¥ãŒã¹
TradingKey - 12æ22æ¥ïŒæææ¥ïŒãç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ãããã»ãã«ãã£ã¹ã¯ã®æ³šå°å€ãWegovyïŒãŠã§ãŽããŒïŒãã®çµå£é å€çãæ£åŒæ¿èªãããããã«ãããäžçåã®æ¿èªçµå£GLP-1ç³»è¥æºæ²»çè¬ãèªçããã

TradingKey - ç³å°¿ç è¬Ozempicã®å€§å¹ å€äžãããã©ã³ãæ°ãçºè¡šããããšãåããŠããšãªã»ãªãªãŒïŒLillyïŒãšããã»ãã«ãã£ã¹ã¯ïŒNovo NordiskïŒã®æ ªäŸ¡ãå€§å¹ ã«äžèœããŸããããã®èšäºå·çæç¹ã§ããšãªã»ãªãªãŒïŒLLYïŒã¯5%以äžãããã»ãã«ãã£ã¹ã¯ïŒNVOïŒã¯3%以äžäžèœããŠããŸãã

TradingKey - ã³ããã¯ã¯ãã³ã®éèŠã§æé·ãæ¯ããããç±³åœè£œè¬å€§æãã¡ã€ã¶ãŒïŒPFEïŒã¯ããã®åŸãã€ãã©ã€ã³ã®åæ»ãšé·æçãªæ ªäŸ¡äžèœã«æ©ãŸãããŠããããããã«ãã£ã¹ã¯ãšãšãªã»ãªãªãŒãæžéè¬åžå Žãæ¯é ããèªç€Ÿã®R&Dæ«æãçµãŠããã¡ã€ã¶ãŒã¯æ¥æé·äžã®è¥æºæ²»çè¬éçºäŒæ¥ã¡ãã«ãµã110%ãã¬ãã¢ã ã§è²·åãããšãã倧èãªæ±ºæãäžããã

TradingKey - ãããŸã§æ³šå°åæžéè¬ãåªããå¹æã§æ¯é ããŠããããæ£è ãå»åž«ã¯ãã䟿å©ã§ã³ã¹ã广çãªçµå£è¬ãåŸ æããŠãããä»ããããã«ãã£ã¹ã¯ã¯çµå£ãŠã§ãŽããŒã泚å°åãšåçã®æžé广ã瀺ãããŒã¿ãçºè¡šãäžæ¹ããšãªã»ãªãªãŒã®çµå£GLP-1é å€ããªãŒãã©ãŒã°ãªããã³ãã¯å¹Žå æ¿èªã2026幎çºå£²ãèŠèŸŒãŸããè¥æºæ²»çã®ãæ³šå°æä»£ãã«çµæ¢ç¬Šãæãããå¯èœæ§ã瀺åããŠããã

ãªã¹ã¯èŠåïŒ
ãã®ãã©ãããã©ãŒã ã«è¡šç€ºãããæŠç¥ãåå¥éæãªãµãŒããã¢ãã«ããŒããã©ãªãªãããã³æŽæ°èšé²ã¯ããŠãŒã¶ãŒã®å人çãªè²¡åç¶æ³ãæè³ç®çããŸãã¯ãªã¹ã¯èš±å®¹åºŠãèæ ®ããŠããŸããããããã¯ãå人åãã®æè³ã¢ããã€ã¹ãé©åæ§ã®è©äŸ¡ããŸãã¯ååŒã®æç€ºãšã¿ãªãããã¹ãã§ã¯ãããŸãããæŠç¥ã®è¡šç€ºé åºããã£ã«ã¿ãŒçµæãããã³ãã¹ãããã©ã€ãããªã©ã®ã©ãã«ã¯ããªã¿ãŒã³ãä¿èšŒããããå人ãžã®é©åæ§ã瀺ããããããã®ã§ã¯ãããŸããã
éå»ã®å®çžŸã¯å°æ¥ã®çµæã瀺ããã®ã§ã¯ãããŸãããããã¯ãã¹ãããã³ã·ãã¥ã¬ãŒã·ã§ã³ã«ããããã©ãŒãã³ã¹ã¯ãå®éã®å£åº§ã§åŸããããªã¿ãŒã³ã衚ããã®ã§ã¯ãããŸãããããã¯ãéžæããéå»ã®æéãããŒã¿å質ãã¢ãã«ã®ä»®å®ãèšç®æ¹æ³ã®åœ±é¿ãåããéå°é©åãªã©ã®ãã€ã¢ã¹ã®åœ±é¿ãåããå¯èœæ§ããããŸããå®éã®çµæã¯ãååŒã³ã¹ããçšéãã¹ãªãããŒãžãæµåæ§ãçºæ¿ã¬ãŒãã®å€åãªã©ã®èŠå ã«ã圱é¿ããã衚瀺ãããçµæãšå€§ããç°ãªãå ŽåããããŸãã
AIããã³å®éçã¢ãã«ã¯ããšã©ãŒããã€ã¢ã¹ãçããããæå³ãããšããã«æ©èœããªãã£ããããå¯èœæ§ããããåžå Žã®å€åãæ£ç¢ºã«äºæž¬ããããšã¯ã§ããŸããããªã¹ã¯ã¬ãã«ã¯ãç¹å®ã®æç¹ã§ç¹å®ã®æ¹æ³ã«ããè©äŸ¡ãããã®ã§ãããèµ·ããåŸãæå€§ã®æå€±ã瀺ããã®ã§ã¯ãããŸãããæäŸ¡èšŒåžã«æè³ãããšãå æ¬ã®äžéšãŸãã¯å šéšã倱ãå¯èœæ§ããããŸãã
ããŒããã©ãªãªã®æ§æèŠçŽ ãã¢ãã«äžã®ä¿ææ¯çãçµã¿å ¥ãæ¥ãŸãã¯é€å€æ¥ãããã³åç §äŸ¡æ Œã¯ããŠãŒã¶ãŒã®å®éã®ä¿æç¶æ³ãååŒå·è¡çµæããŸãã¯å·è¡å¯èœäŸ¡æ Œã衚ããã®ã§ã¯ãããŸãããããŒã¿ãšãªãµãŒãã®èŠè§£ã¯é å»¶ããå¯èœæ§ããããåžå Žãã¢ãã«ãæŽæ°ããããšå€æŽãããå¯èœæ§ããããŸãããŠã©ãããªã¹ããžã®é ç®ã®è¿œå ã¯æ å ±è¿œè·¡ã®ã¿ãç®çãšããŠãããèªåçã«ååŒãå®è¡ãããããã§ã¯ãããŸããã
Proãµãã¹ã¯ãªãã·ã§ã³ã«ãããé¢é£ããã³ã³ãã³ããæ©èœãžã®ã¢ã¯ã»ã¹ãæäŸãããŸãããªãµãŒãã®çµè«ã®æ£ç¢ºæ§ãæŠç¥ã®æå¹æ§ãæè³ãªã¿ãŒã³ã®ããããä¿èšŒãããã®ã§ã¯ãããŸããããã®ãã©ãããã©ãŒã ã®ã³ã³ãã³ãã®ã¿ã«åºã¥ããŠååŒã®æ±ºå®ãäžããªãã§ãã ãããå¿ èŠã«å¿ããŠã管èœåºåå ã®é©åãªè³æ Œãæã€å°éå®¶ã«çžè«ããŠãã ããã

